These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22202235)

  • 1. [Randomized phase II trial to compare S-1 and S-1/PSK for advanced or recurrent gastric cancer-lessons from the results].
    Yoshikawa T; Tsuburaya A; Saze Z; Aoyama T; Hasegawa S; Kanemoto A; Terashima M; Tahara H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1909-11. PubMed ID: 22202235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [S-1/krestin immunochemotherapy for patients with advanced gastric cancer].
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A; Rino Y; Masuda M
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1921-3. PubMed ID: 22202239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
    Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
    Ueda Y; Fujimura T; Kinami S; Hirono Y; Yamaguchi A; Naitoh H; Tani T; Kaji M; Yamagishi H; Miwa K;
    Jpn J Clin Oncol; 2006 Aug; 36(8):519-22. PubMed ID: 16803844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of patients with advanced gastric cancer undergoing S-1/CDDP combined neoadjuvant chemotherapy].
    Kikuchi D; Ishii Y; Saitou M; Yamada M; Takenoshita S
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1113-7. PubMed ID: 21772093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
    Kim JY; Do YR; Park KU; Kim JG; Chae YS; Kim MK; Lee KH; Ryoo HM; Bae SH; Baek JH; Song HS
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):527-32. PubMed ID: 20461377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
    Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
    Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2).
    Nakata B; Tsuji A; Mitachi Y; Taenaka N; Kamano T; Oikawa K; Onoda N; Kambe M; Takahashi M; Shirasaka T; Morita S; Sakamoto J; Tanaka Y; Saji S; Hirakawa K
    Oncology; 2010; 79(5-6):337-42. PubMed ID: 21430401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly paclitaxel following fixed three cycles of S-1-based chemotherapy for advanced gastric cancer.
    Ohashi M; Kanda T; Kobayashi T; Hirota M; Hayami M; Yajima K; Matsuki A; Kosugi S; Hatakeyama K;
    Hepatogastroenterology; 2011; 58(106):652-8. PubMed ID: 21674889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of advanced gastric cancer with multiple liver metastasis responding to S-1 and irinotecan combination therapy].
    Kuga T; Oka K; Yamashita A; Fujii Y; Hanashima M; Hamano K
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1333-6. PubMed ID: 21829075
    [No Abstract]   [Full Text] [Related]  

  • 14. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination chemotherapy of S-1/low-dose CDDP/lentinan for advanced gastric cancer].
    Hori T; Ikehara T; Takatsuka S; Fukuoka T; Tendo M; Tezuka K; Dan N; Nishino H; Hirakawa K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):293-5. PubMed ID: 21368498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial).
    Okuno K; Aoyama T; Oba K; Yokoyama N; Matsuhashi N; Kunieda K; Nishimura Y; Akamatsu H; Kobatake T; Morita S; Yoshikawa T; Sakamoto J; Saji S
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):65-71. PubMed ID: 29094178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer.
    Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Sugai H; Akaike H; Fujii H
    Oncology; 2008; 74(3-4):143-9. PubMed ID: 18708731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
    Kemmochi T; Egawa T; Mihara Y; Irino T; Ito Y; Nagashima A; Makino H; Yamamuro W
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2351-3. PubMed ID: 22202379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
    Baba E; Esaki T; Ariyama H; Mitsugi K; Morikita T; Fujishima H; Kusaba H; Nakano S; Akashi K
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):611-7. PubMed ID: 21116623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.